170 related articles for article (PubMed ID: 15155103)
21. Essential thrombocythaemia.
Bentley MA; Taylor KM; Wright SJ
Med J Aust; 1999 Aug; 171(4):210-3. PubMed ID: 10494240
[TBL] [Abstract][Full Text] [Related]
22. [Anagrelide in primary thrombocythemia].
Knutsen H; Hysing J
Tidsskr Nor Laegeforen; 2001 May; 121(12):1478-82. PubMed ID: 11449771
[TBL] [Abstract][Full Text] [Related]
23. Two cases of pediatric essential thrombocythemia managed effectively with hydroxyurea.
Dua V; Yadav SP; Kumar V; Saxena R; Sachdeva A
Int J Hematol; 2012 Dec; 96(6):810-3. PubMed ID: 23054653
[TBL] [Abstract][Full Text] [Related]
24. Practical approach to treating essential thrombocythaemia: case studies.
Reilly JT
Eur J Haematol Suppl; 2007 Oct; (68):40-2. PubMed ID: 17727566
[No Abstract] [Full Text] [Related]
25. [Anagrelide in the treatment of essential thrombocythemia (ET) and other myeloproliferative disorders with thrombocythemia based on data from patient register in the CR].
Penka M; Doubek M; Schwarz J; Pytlík R; Dulícek P; Kissová J; Hlusí A; Vozobulová V; Cerná O; Brychtová Y; Szotkowski T; Volková Z; Seghetová J; Schutzová M; Hadacová I; Hochová I; Voglová J; Siroký O; Belada D; Lhot'anová T; Bubeník B; Vránová M; Micaníková M; Dusek L
Vnitr Lek; 2006 May; 52(5):498-503. PubMed ID: 16771099
[TBL] [Abstract][Full Text] [Related]
26. [The effectiveness of anagrelide treatment in patients with Ph negative myeloproliferative diseases: influence on the incidence of thrombosis in the data from the Registry of patients with essential thrombocythemia and thrombocythemia associated with other myeloproliferative diseases treated with Thromboreductin® to the end of 2012].
Penka M; Schwarz J; Ovesná P; Cervinek L; Dulíček P; Pospíšilová D; Kissová J; Pavlík T;
Vnitr Lek; 2013 Jun; 59(6):516-31. PubMed ID: 23808749
[TBL] [Abstract][Full Text] [Related]
27. SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia.
Verstovsek S; Komatsu N; Gill H; Jin J; Lee SE; Hou HA; Sato T; Qin A; Urbanski R; Shih W; Zagrijtschuk O; Zimmerman C; Mesa RA
Future Oncol; 2022 Sep; 18(27):2999-3009. PubMed ID: 35924546
[TBL] [Abstract][Full Text] [Related]
28. Thrombocytosis.
Schafer AI
N Engl J Med; 2004 Mar; 350(12):1211-9. PubMed ID: 15028825
[No Abstract] [Full Text] [Related]
29. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
[TBL] [Abstract][Full Text] [Related]
30. Management of refractory essential thrombocythemia with anagrelide in a patient undergoing hemodialysis.
Mesquita Mdo C; Sol EB; Malarme M; Noubouossie D; Demulder AC
Clin Ther; 2009 Nov; 31(11):2559-64. PubMed ID: 20110000
[TBL] [Abstract][Full Text] [Related]
31. The Use of Anagrelide in Myeloproliferative Neoplasms, with Focus on Essential Thrombocythemia.
Birgegård G
Curr Hematol Malig Rep; 2016 Oct; 11(5):348-55. PubMed ID: 27497846
[TBL] [Abstract][Full Text] [Related]
32. How to manage essential thrombocythemia.
Finazzi G
Leukemia; 2012 May; 26(5):875-82. PubMed ID: 22051530
[TBL] [Abstract][Full Text] [Related]
33. Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.
Fu R; Zhang L; Yang R
Br J Haematol; 2013 Nov; 163(3):295-302. PubMed ID: 24032343
[TBL] [Abstract][Full Text] [Related]
34. [Diagnosis and treatment of essential thrombocythemia].
Kuramoto A
Rinsho Ketsueki; 1995 May; 36(5):480-6. PubMed ID: 7783354
[TBL] [Abstract][Full Text] [Related]
35. Essential thrombocythemia: past and present.
Fabris F; Randi ML
Intern Emerg Med; 2009 Oct; 4(5):381-8. PubMed ID: 19636672
[TBL] [Abstract][Full Text] [Related]
36. Essential thrombocythaemia treatment options: addressing patient-specific needs.
Birgegård G
Eur J Haematol Suppl; 2007 Oct; (68):27-31. PubMed ID: 17727563
[No Abstract] [Full Text] [Related]
37. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
38. Management of essential thrombocythemia.
Cervantes F
Hematology Am Soc Hematol Educ Program; 2011; 2011():215-21. PubMed ID: 22160037
[TBL] [Abstract][Full Text] [Related]
39. How would I manage a case of essential thrombocythaemia presenting with an ischaemic toe.
McLornan D; McMullin M
Hematol Oncol; 2008 Mar; 26(1):3-7. PubMed ID: 17968848
[TBL] [Abstract][Full Text] [Related]
40. Anagrelide: what was new in 2004 and 2005?
Petrides PE
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
